ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2636

IgA Vasculitis – The Second Most Common Systemic Vasculitis In Adults In Slovenia

Alojzija Hocevar1, ŽIga Rotar1, Jaka Ostrovrsnik1, Vesna Jurcic2, Jelka Lindic3 and Matija Tomsic4,5, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Institute of Pathology, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, 3Department of Nephrology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 4Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, 5Faculty of Medicine, Unversity Ljubljana, Ljubljana, Slovenia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Henoch-Schönlein purpura and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis III

Session Type: Abstract Submissions (ACR)

Background/Purpose: IgA vasculitis (IgAV) is assumed to be rare in adults. Reported annual incidence rates vary between 0.8 and 1.8 cases per 100,000 adults.1 Our aim was to determine the incidence rate of histologically confirmed IgAV in our country.

Methods: A retrospective patient chart review of adult patients diagnosed with IgAV was performed at the departments of rheumatology, nephrology and dermatovenerology at an integrated secondary/tertiary university teaching hospital, which is the only hospital serving a region representing approximately a quarter of the national population. In order not to miss any cases managed by the few private dermatovenerology and nephrology outpatient clinics, the attached medical faculty’s Institute of Pathology provided a list of all histologically proven cases of IaAV in the region. The annual incidence rate of histologically confirmed IgAV was calculated. 

Results: From June 2010 to June 2013 48, 3, and 7 new cases of IgAV were identified at the departments of rheumatology, nephrology, and dermatovenerology, respectively in a well-defined region with a population of 517,445 white Caucasians aged 20 years or above. No additional cases were identified from records retrieved at the Institute of Pathology. The estimated annual incidence rate of IgAV is 3.7 (95% CI 2.2–5.7) per 100,000 adults. The largest proportion of cases were identified in the winter (31.0% cases) and the smallest in the spring (17.2% cases). Male to female ratio was 1.6.

Conclusion: The annual incidence rate of IgAV of 3.7 per 100,000 adults may be underestimated due to retrospective case ascertainment and inclusion of histologically confirmed cases only, yet IgAV none the less represents the second most common systemic vasculitis among adults in our population, second only to giant cell arteritis with an estimated annual incidence rate of 4.7 per100,000 adults, which is in striking discord with previous reports.1

Reference: 1 Penny K, Fleming M, Kazmierczak D, Thomas A. An epidemiological study of Henoch-Schönlein purpura. Paediatr Nurs. 2010;22:30-5.


Disclosure:

A. Hocevar,
None;

Rotar,
None;

J. Ostrovrsnik,
None;

V. Jurcic,
None;

J. Lindic,
None;

M. Tomsic,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/iga-vasculitis-the-second-most-common-systemic-vasculitis-in-adults-in-slovenia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology